Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study

BACKGROUND: The treatment of anemia in patients with cardiorenal syndrome (CRS) is based mainly on intravenous (IV) iron therapy and/or erythropoiesis-stimulating agents (ESAs). There are concerns about the safety of ESAs due to a potentially higher risk for stroke and malignancy. OBJECTIVE: We aime...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiorenal Med
Autors principals: Ben-Assa, Eyal, Shacham, Yacov, Shashar, Moshe, Leshem-Rubinow, Eran, Gal-Oz, Amir, Schwartz, Idit F., Schwartz, Doron, Silverberg, Donald S., Chernin, Gil
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2015
Matèries:
Original Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4662275/
https://ncbi.nlm.nih.gov/pubmed/26648941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000433564
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars